When people with a mental disability fail to conceive naturally, they also like to be considered for fertility treatment. However, the GP, gynaecologist or fertility specialist may question their parenting competence. Physicians may and can refuse fertility treatment if they have reasons to suspect that the child will have a poor quality of life. We are using a case history to outline how a well-considered multidisciplinary recommendation can be made that does justice to the patient's request while causing the least amount of grief. The guiding principle in doing so is the moral consideration that the harm to the future child should not outweigh the harm to the parents.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Protective effect of quercetin loaded on bifunctional periodic mesoporous organosilica against damage induced by irradiation on the male reproductive system.
J Mater Sci Mater Med
January 2025
Applied Chemistry Research Laboratory, Department of Chemistry, Faculty of Science, University of Zanjan, Zanjan, Iran.
Preserving fertility is important in men under radiation therapy because healthy cells are also affected by radiation. Supplementation with antioxidants is a controversial issue in this process. Designing a biocompatible delivery system containing hydrophobic antioxidants to release control may solve these disagreements.
View Article and Find Full Text PDFCurrent drawbacks and future perspectives in the diagnosis and treatment of male factor infertility, with a focus on FSH treatment: an expert opinion.
J Endocrinol Invest
January 2025
Department of Medicine, University of Padova, Padua, Italy.
Purpose: Infertility is defined as the inability to conceive after 1 year of unprotected intercourse, affecting approximately 15-20% of couples in Western countries. It is a shared problem within the couple; when the main issue lies with one of the partners, it is preferable to refer to "male factor" or "female factor" infertility rather than simply male or female infertility. Despite male factor infertility accounting for half of all couple infertility cases, the clinical approach to the male partner is not uniformly standardized across international guidelines.
View Article and Find Full Text PDFFrom biological marker to clinical application: the role of anti-Müllerian hormone (AMH) for delayed puberty and idiopathic non-obstructive azoospermia in males.
Endocr Connect
January 2025
X Jiang, Human Sperm Bank, Sichuan University West China Second University Hospital, Chengdu, China.
Anti-Müllerian hormone (AMH), a biomarker secreted by Sertoli cells in the testes, has emerged as a critical indicator of male reproductive function with significant clinical application potential. AMH reflects Sertoli cell activity and plays a pivotal role across different stages of male gonadal function. Firstly, in prepubertal males, AMH levels are crucial for assessing testicular development and the progression of puberty, with delayed or insufficient AMH secretion often being associated with disorders like delayed puberty.
View Article and Find Full Text PDFRecommendations on the management of meningioma and sex hormone therapy: The results of a collaborative effort between neurosurgical, endocrine and gynecological societies.
Brain Spine
December 2024
Department of Gynecology, CHU de Liege, Liège, Belgium.
Introduction: Exogenous and endogenous sex hormones, especially Progesterone agonists, may be causally linked to meningioma progression. Cessation of treatment leads to stabilization or regression of Progestin-induced meningioma. In many cases, avoiding sex hormone therapy may be possible in the context of meningioma treatment.
View Article and Find Full Text PDFThe role of luteinizing hormone activity in spermatogenesis: from physiology to clinical practice.
Reprod Biol Endocrinol
January 2025
Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.
The production of spermatozoa, a process known as spermatogenesis, is primarily controlled by follicle-stimulating hormone (FSH) and luteinizing hormone (LH)-driven testosterone. LH acts on the Leydig cells, stimulating steroid production, predominantly testosterone, and activating critical inter-related spermatogenesis regulatory pathways. Despite evidence that exogenous gonadotropins containing LH activity can effectively restore spermatogenesis in males with hypogonadotropic hypogonadism, the use of these drugs to treat other forms of male infertility is the subject of an ongoing debate.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!